Diabetic Nephropathy - Pipeline Review, H2 2017

Date: August 22, 2017
Pages: 214
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: DFA92E5C46DEN
Leaflet:

Download PDF Leaflet

Diabetic Nephropathy - Pipeline Review, H2 2017
Diabetic Nephropathy - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2017, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 10, 1, 32, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Diabetic Nephropathy - Overview
Diabetic Nephropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diabetic Nephropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Nephropathy - Companies Involved in Therapeutics Development
AbbVie Inc
Allergan Plc
Antisense Therapeutics Ltd
Aptevo Therapeutics Inc
Araim Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BLR Bio LLC
Boehringer Ingelheim GmbH
Cellmid Ltd
ChemoCentryx Inc
CSL Ltd
Daiichi Sankyo Company Ltd
DiaMedica Therapeutics Inc
Dynamis Therapeutics Inc
Galectin Therapeutics Inc
GenKyoTex SA
Gilead Sciences Inc
GNI Group Ltd
Islet Sciences Inc
Johnson & Johnson
MediPost Co Ltd
Mesoblast Ltd
Mitsubishi Tanabe Pharma Corp
MorphoSys AG
Noxxon Pharma AG
Omeros Corp
Paranta Biosciences Ltd
PhiloGene Inc
PhytoHealth Corp
ProMetic Life Sciences Inc
Redx Pharma Plc
Sarfez Pharmaceuticals Inc
Serodus ASA
Teijin Pharma Ltd
Theravance Biopharma Inc
Twoxar Inc
Vascular Pharmaceuticals Inc
Vicore Pharma AB
XORTX Pharma Corp
Diabetic Nephropathy - Drug Profiles
11-RVIVIT - DRUG PROFILE
A-717 - Drug Profile
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
apararenone - Drug Profile
APD-371 - Drug Profile
APX-115 - Drug Profile
ASP-8232 - Drug Profile
atesidorsen sodium - Drug Profile
atrasentan hydrochloride - Drug Profile
BI-685509 - Drug Profile
BI-690517 - Drug Profile
BI-703704 - Drug Profile
BLR-200 - Drug Profile
C-21 - Drug Profile
canagliflozin - Drug Profile
CCX-140 - Drug Profile
Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile
cenicriviroc mesylate - Drug Profile
cibinetide - Drug Profile
CSL-346 - Drug Profile
Cyndacel-M - Drug Profile
DM-199 - Drug Profile
DM-399 - Drug Profile
Drugs for Diabetic Nephropathy - Drug Profile
DT-23552 - Drug Profile
DYN-12 - Drug Profile
emapticap pegol - Drug Profile
esaxerenone - Drug Profile
finerenone - Drug Profile
FM-1302 - Drug Profile
GKT-136901 - Drug Profile
GKT-831 - Drug Profile
GLY-230 - Drug Profile
GRMD-02 - Drug Profile
GS-444217 - Drug Profile
IL-233 - Drug Profile
IP-9 - Drug Profile
JD-5037 - Drug Profile
JNJ-39933673 - Drug Profile
MG-132 - Drug Profile
Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile
MOR-107 - Drug Profile
MPC-300IV - Drug Profile
Orbcel-M - Drug Profile
PBI-4050 - Drug Profile
PBI-4425 - Drug Profile
PBI-4547 - Drug Profile
PHN-033 - Drug Profile
pirfenidone - Drug Profile
Recombinant Protein for Diabetic Nephropathy - Drug Profile
Recombinant Protein to Antagonize VEGFR-2 for Diabetic Nephropathy and Oncology - Drug Profile
REDX-06109 - Drug Profile
SCO-272 - Drug Profile
SER-150 - Drug Profile
Small Molecules for Diabetic Nephropathy - Drug Profile
Small Molecules to Inhibit AOC3 for Diabetic Nephropathy - Drug Profile
Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile
Small Molecules to Inhibit Rho Kinase for Hypertension and Diabetic Nephropathy - Drug Profile
SP-20202 - Drug Profile
Stem Cell Therapy for Diabetic Nephropathy and Autoimmune Disorders - Drug Profile
TBE-31 - Drug Profile
TD-0714 - Drug Profile
TD-1439 - Drug Profile
TMX-049 - Drug Profile
TNFR x TWEAKR - Drug Profile
VAR-400 - Drug Profile
VPI-2690B - Drug Profile
VS-105 - Drug Profile
Wnt-001 - Drug Profile
XRX-108 - Drug Profile
XRX-221 - Drug Profile
Diabetic Nephropathy - Dormant Projects
Diabetic Nephropathy - Discontinued Products
Diabetic Nephropathy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Diabetic Nephropathy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Diabetic Nephropathy - Pipeline by AbbVie Inc, H2 2017
Diabetic Nephropathy - Pipeline by Allergan Plc, H2 2017
Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H2 2017
Diabetic Nephropathy - Pipeline by Aptevo Therapeutics Inc, H2 2017
Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, H2 2017
Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals Inc, H2 2017
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, H2 2017
Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H2 2017
Diabetic Nephropathy - Pipeline by Bayer AG, H2 2017
Diabetic Nephropathy - Pipeline by BLR Bio LLC, H2 2017
Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Diabetic Nephropathy - Pipeline by Cellmid Ltd, H2 2017
Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, H2 2017
Diabetic Nephropathy - Pipeline by CSL Ltd, H2 2017
Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Diabetic Nephropathy - Pipeline by DiaMedica Therapeutics Inc, H2 2017
Diabetic Nephropathy - Pipeline by Dynamis Therapeutics Inc, H2 2017
Diabetic Nephropathy - Pipeline by Galectin Therapeutics Inc, H2 2017
Diabetic Nephropathy - Pipeline by GenKyoTex SA, H2 2017
Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, H2 2017
Diabetic Nephropathy - Pipeline by GNI Group Ltd, H2 2017
Diabetic Nephropathy - Pipeline by Islet Sciences Inc, H2 2017
Diabetic Nephropathy - Pipeline by Johnson & Johnson, H2 2017
Diabetic Nephropathy - Pipeline by MediPost Co Ltd, H2 2017
Diabetic Nephropathy - Pipeline by Mesoblast Ltd, H2 2017
Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Diabetic Nephropathy - Pipeline by MorphoSys AG, H2 2017
Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H2 2017
Diabetic Nephropathy - Pipeline by Omeros Corp, H2 2017
Diabetic Nephropathy - Pipeline by Paranta Biosciences Ltd, H2 2017
Diabetic Nephropathy - Pipeline by PhiloGene Inc, H2 2017
Diabetic Nephropathy - Pipeline by PhytoHealth Corp, H2 2017
Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc, H2 2017
Diabetic Nephropathy - Pipeline by Redx Pharma Plc, H2 2017
Diabetic Nephropathy - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017
Diabetic Nephropathy - Pipeline by Serodus ASA, H2 2017
Diabetic Nephropathy - Pipeline by Teijin Pharma Ltd, H2 2017
Diabetic Nephropathy - Pipeline by Theravance Biopharma Inc, H2 2017
Diabetic Nephropathy - Pipeline by Twoxar Inc, H2 2017
Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals Inc, H2 2017
Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H2 2017
Diabetic Nephropathy - Pipeline by XORTX Pharma Corp, H2 2017
Diabetic Nephropathy - Dormant Projects, H2 2017
Diabetic Nephropathy - Dormant Projects, H2 2017 (Contd..1), H2 2017
Diabetic Nephropathy - Dormant Projects, H2 2017 (Contd..2), H2 2017
Diabetic Nephropathy - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Diabetic Nephropathy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

AbbVie Inc
Allergan Plc
Antisense Therapeutics Ltd
Aptevo Therapeutics Inc
Araim Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BLR Bio LLC
Boehringer Ingelheim GmbH
Cellmid Ltd
ChemoCentryx Inc
CSL Ltd
Daiichi Sankyo Company Ltd
DiaMedica Therapeutics Inc
Dynamis Therapeutics Inc
Galectin Therapeutics Inc
GenKyoTex SA
Gilead Sciences Inc
GNI Group Ltd
Islet Sciences Inc
Johnson & Johnson
MediPost Co Ltd
Mesoblast Ltd
Mitsubishi Tanabe Pharma Corp
MorphoSys AG
Noxxon Pharma AG
Omeros Corp
Paranta Biosciences Ltd
PhiloGene Inc
PhytoHealth Corp
ProMetic Life Sciences Inc
Redx Pharma Plc
Sarfez Pharmaceuticals Inc
Serodus ASA
Teijin Pharma Ltd
Theravance Biopharma Inc
Twoxar Inc
Vascular Pharmaceuticals Inc
Vicore Pharma AB
XORTX Pharma Corp
Skip to top


Nephropathy - Pipeline Review, H1 2016 US$ 2,000.00 Apr, 2016 · 59 pages
Nephropathy - Pipeline Review, H2 2015 US$ 2,000.00 Dec, 2015 · 57 pages

Ask Your Question

Diabetic Nephropathy - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: